PREVIEW of AHA 2020 Scientific Sessions: Late-breaking Science, Days 4 and 5

News
Article

Preview days 4 and 5 of the American Heart Association 2020 live late-breaking science sessions. Decide what you need to watch and when.

The American Heart Association 2020 Scientific Sessions continue on Monday and Tuesday, November 16 and 17, and include late-breaking clinical trial results from VITAL-AF, MSTOPS, RHAPSODY, MyROAD, and more.

To help your advance planning, click through the agenda for each session, below. For Friday, Saturday, and Sunday's sessions, click here.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults / image credit ©H_Ko/stock.adobe.com

FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults

Luke Halpern
May 8th 2025
Article

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Adolescent Hyperglycemia, Insulin Resistance Drive Early Cardiac Structural Changes / image credit Andrew Agbaje, MD, MPH, PhD Courtesy of University of Eastern Finland

Adolescent Hyperglycemia, Insulin Resistance Drive Early Cardiac Structural Changes, Novel Cohort Study Finds

Grace Halsey
May 2nd 2025
Article

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose

Sydney Jennings
April 25th 2025
Article

Your daily dose of the clinical news you may have missed.

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection / image courtesy of University of Oxford

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection

Grace Halsey
April 21st 2025
Article

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

© 2025 MJH Life Sciences

All rights reserved.